You are about to leave Helsinn's Corporate US Website.

Please click 'Continue to external site' if you want to continue.

Pipeline

We’re working to identify more unmet medical needs and focus our research where it is needed most. Our growing pipeline includes therapies aimed at providing new solutions in cancer care and rare diseases where no options currently exist, with a goal to help lift the burden of cancer for patients.

Robust R&D Pipeline with significant potential

Near-term and long-term pipeline, securing launches over the coming years.

Cancer therapeutics

Infigratinib*

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
2nd Line Cholangiocarcinoma1
1st Line Cholangiocarcinoma
Adjuvant Urothelial Cancer

HM06

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Solid Tumours with RET mutations

Chlormethine

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
China – Gel – MF-CTCL2

Cancer supportive care

Fosnetupitant

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Japan - IV - CINV3

Fosnetupitant - Palonosetron

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Paediatric CINV3

Fosnetupitant - Palonosetron

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
China - IV - CINV3

Anamorelin

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Global – Cancer Anorexia-Cachexia in NSCLC4 patients
China – Cancer Anorexia-Cachexia in NSCLC4 patients

Others

HM04

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Ghrelin Receptor Antagonist - Prader-Willi Syndrome

HM01

Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Ghrelin Receptor Agonist